Royalty Pharma (RPRX) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic highlights and financial performance

• Achieved 14–16% growth in portfolio receipts for 2025, with strong returns on invested capital (15.7%) and equity (22.9%).

• Internalized external management, reducing costs and improving governance.

• Consistently outperformed analyst expectations in 15 of the last 22 quarters.

• Maintains a disciplined investment process, focusing on late-stage or approved products, with 90% of development-stage investments receiving approval.

• Achieved 2025 portfolio receipts guidance midpoint of $3.225 billion, reflecting ~15% year-over-year growth.

Market trends and growth drivers

• Biopharma royalty market averaged $7.1 billion in annual transactions over the past five years, with 2025 reaching a record $10 billion.

• Synthetic royalties are rapidly growing, accounting for $4.7 billion in 2025, up 50% from 2024.

• Synthetic royalties now routinely discussed at board level, with growing acceptance as a funding modality.

• Royalty funding offers non-dilutive, flexible capital compared to traditional debt or equity.

• Expansion into China and other international markets seen as significant future growth opportunities.

Portfolio and pipeline outlook

• Eight transactions executed in 2025 for nine therapies, with a highly selective 2% conversion rate from initial reviews.

• 86% of invested capital is in approved products, with only 3% in failed investments.

• Development-stage pipeline includes 20 products, with several expected launches in 2026 and beyond.

• Combined peak sales for pipeline products estimated at over $43 billion, translating to $2.1 billion in annual peak royalties.

• Multiple pivotal trial readouts and launches expected through 2027, supporting long-term growth.